Nicholas Hoffman & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Nicholas Hoffman & Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Buy	738 +6	+0.8%	+$2.66K	0.01%	274
2026 Q1	$327K	Hold	732	–	–	0.01%	278
2025 Q4	$332K	Hold	732	–	–	0.01%	265
2025 Q3	$287K	Hold	732	–	–	0.01%	267
2025 Q2	$326K	Hold	732	–	–	0.01%	246
2025 Q1	$355K	Hold	732	–	–	0.01%	229
2024 Q4	$295K	Hold	732	–	–	0.01%	242
2024 Q3	$340K	Sell	732 -100	-12%	-$48K	0.01%	236
2024 Q2	$390K	Buy	832 +100	+14%	+$43.4K	0.02%	217
2024 Q1	$306K	Buy	732 +96	+15%	+$40.6K	0.02%	238
2023 Q4	$259K	Buy	636 +24	+4%	+$8.87K	0.02%	247
2023 Q3	$213K	Hold	612	–	–	0.02%	256
2023 Q2	$215K	Sell	612 -289	-32%	-$97.4K	0.01%	255
2023 Q1	$284K	Hold	901	–	–	0.03%	225
2022 Q4	$260K	Hold	901	–	–	0.03%	227
2022 Q3	$261K	Hold	901	–	–	0.01%	216
2022 Q2	$254K	Buy	901 +17	+2%	+$4.55K	0.01%	223
2022 Q1	$231K	Buy	+884	New	+$210K	0.01%	258

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nicholas Hoffman & Company's VRTX Position: Q2 2026 in Review

Nicholas Hoffman & Company increased its Vertex Pharmaceuticals (VRTX) stake by 0.82% in Q2 2026, buying an estimated $2.66K and bringing the position to 738 shares worth $367K. The position accounts for 0.01% of the portfolio, ranked #274.

Nicholas Hoffman & Company first reported a position in VRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $390K in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Nicholas Hoffman & Company held 738 shares of Vertex Pharmaceuticals worth $367K as of Q2 2026.
Nicholas Hoffman & Company bought 6 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.66K.
Vertex Pharmaceuticals made up 0.01% of Nicholas Hoffman & Company's portfolio in Q2 2026, its #274 holding.
Nicholas Hoffman & Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
Nicholas Hoffman & Company's Vertex Pharmaceuticals position peaked at $390K in Q2 2024.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nicholas Hoffman & Company's 13F filing for Q2 2026, filed 4 Aug 2026.